Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence

Autor: William H. Polonsky, Ruo-Ding Tan, J. Y. Zhu, Ginger S. Carls, S. V. Edelman, Edward Tuttle, J. Yee
Rok vydání: 2017
Předmět:
Zdroj: Obesity Science & Practice. 3:342-351
ISSN: 2055-2238
DOI: 10.1002/osp4.116
Popis: SummaryAims The study aims to examine real-world weight change and the role of medication adherence among patients with type 2 diabetes who initiated one of three drug classes: glucagon-like peptide-1 receptor agonist (GLP-1RA), dipeptidyl peptidase-4 inhibitor (DPP4) and sulfonylureas (SUs). Materials and methods A cohort of patients initiating one of the three drug classes was selected from a large US database of integrated electronic medical record and administrative claims. Adherence was defined as per cent of days covered ≥80% during the year following drug initiation. Weight change was calculated from drug initiation (−180, +30 d) to 1 year (±90 d) later. Multivariate regression controlled for baseline differences between adherent and poorly adherent patients and the addition of another drug class during follow-up. Results The study included 833 GLP-1RA, 2,272 DPP4 and 2,713 SU patients who contributed 2,279, 6,602 and 7,429 observations respectively. Patients initiating a GLP-1RA achieved the largest weight change (−2.46 kg of GLP-1RA, −1.26 kg of DPP4 and 0.18 kg of SU, P
Databáze: OpenAIRE
Externí odkaz: